Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MSN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MSN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MSN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MSN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MSN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MSN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MSN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1903829110 | Oral cavity | LP | positive regulation of cellular protein localization | 127/4623 | 276/18723 | 7.52e-15 | 9.81e-13 | 127 |
GO:1903362110 | Oral cavity | LP | regulation of cellular protein catabolic process | 119/4623 | 255/18723 | 1.52e-14 | 1.76e-12 | 119 |
GO:003238616 | Oral cavity | LP | regulation of intracellular transport | 145/4623 | 337/18723 | 8.58e-14 | 8.27e-12 | 145 |
GO:003238819 | Oral cavity | LP | positive regulation of intracellular transport | 97/4623 | 202/18723 | 4.79e-13 | 4.30e-11 | 97 |
GO:0009896110 | Oral cavity | LP | positive regulation of catabolic process | 187/4623 | 492/18723 | 2.30e-11 | 1.58e-09 | 187 |
GO:0045732110 | Oral cavity | LP | positive regulation of protein catabolic process | 103/4623 | 231/18723 | 2.68e-11 | 1.81e-09 | 103 |
GO:0031331110 | Oral cavity | LP | positive regulation of cellular catabolic process | 163/4623 | 427/18723 | 3.03e-10 | 1.59e-08 | 163 |
GO:0043254110 | Oral cavity | LP | regulation of protein-containing complex assembly | 163/4623 | 428/18723 | 3.72e-10 | 1.92e-08 | 163 |
GO:1903364110 | Oral cavity | LP | positive regulation of cellular protein catabolic process | 72/4623 | 155/18723 | 2.93e-09 | 1.28e-07 | 72 |
GO:0031334110 | Oral cavity | LP | positive regulation of protein-containing complex assembly | 99/4623 | 237/18723 | 4.83e-09 | 2.00e-07 | 99 |
GO:1901654110 | Oral cavity | LP | response to ketone | 78/4623 | 194/18723 | 1.24e-06 | 3.03e-05 | 78 |
GO:001648214 | Oral cavity | LP | cytosolic transport | 69/4623 | 168/18723 | 2.03e-06 | 4.65e-05 | 69 |
GO:0048732110 | Oral cavity | LP | gland development | 149/4623 | 436/18723 | 4.51e-06 | 9.17e-05 | 149 |
GO:190211513 | Oral cavity | LP | regulation of organelle assembly | 71/4623 | 186/18723 | 2.94e-05 | 4.58e-04 | 71 |
GO:002240613 | Oral cavity | LP | membrane docking | 38/4623 | 86/18723 | 5.97e-05 | 8.13e-04 | 38 |
GO:0032535110 | Oral cavity | LP | regulation of cellular component size | 128/4623 | 383/18723 | 6.56e-05 | 8.80e-04 | 128 |
GO:000716319 | Oral cavity | LP | establishment or maintenance of cell polarity | 79/4623 | 218/18723 | 8.84e-05 | 1.11e-03 | 79 |
GO:003601012 | Oral cavity | LP | protein localization to endosome | 14/4623 | 24/18723 | 4.52e-04 | 4.30e-03 | 14 |
GO:009892714 | Oral cavity | LP | vesicle-mediated transport between endosomal compartments | 21/4623 | 43/18723 | 5.18e-04 | 4.82e-03 | 21 |
GO:0022604110 | Oral cavity | LP | regulation of cell morphogenesis | 101/4623 | 309/18723 | 8.65e-04 | 7.50e-03 | 101 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MSN | SNV | Missense_Mutation | | c.1189N>A | p.Glu397Lys | p.E397K | P26038 | protein_coding | tolerated(0.32) | possibly_damaging(0.61) | TCGA-A2-A0YT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
MSN | SNV | Missense_Mutation | | c.1678C>T | p.Arg560Cys | p.R560C | P26038 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
MSN | SNV | Missense_Mutation | | c.1507N>T | p.Arg503Cys | p.R503C | P26038 | protein_coding | deleterious(0.01) | probably_damaging(0.953) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MSN | SNV | Missense_Mutation | | c.855N>A | p.Met285Ile | p.M285I | P26038 | protein_coding | tolerated(0.23) | benign(0.029) | TCGA-C8-A12U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MSN | SNV | Missense_Mutation | rs753856958 | c.659N>G | p.Val220Gly | p.V220G | P26038 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A1N5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MSN | SNV | Missense_Mutation | rs770945316 | c.299G>A | p.Arg100His | p.R100H | P26038 | protein_coding | tolerated(0.58) | benign(0.068) | TCGA-LL-A9Q3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Immunotherapy | herceptin | CR |
MSN | SNV | Missense_Mutation | novel | c.1034A>G | p.Glu345Gly | p.E345G | P26038 | protein_coding | tolerated(0.19) | benign(0.007) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
MSN | insertion | In_Frame_Ins | novel | c.342_343insCTCACCTTACCCTTACCCTCCACTTGCATCCTTCTCCCAAAAAAC | p.Asp114_Ile115insLeuThrLeuProLeuProSerThrCysIleLeuLeuProLysAsn | p.D114_I115insLTLPLPSTCILLPKN | P26038 | protein_coding | | | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
MSN | SNV | Missense_Mutation | novel | c.322N>A | p.Glu108Lys | p.E108K | P26038 | protein_coding | tolerated(0.09) | possibly_damaging(0.47) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MSN | SNV | Missense_Mutation | rs778459733 | c.835N>T | p.Arg279Trp | p.R279W | P26038 | protein_coding | deleterious(0.03) | possibly_damaging(0.598) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |